Jing Li
About Jing Li
Jing Li is a Senior Director of Medicinal Chemistry at LifeMine Therapeutics, with extensive expertise in drug design, synthesis, and safety. He has held various significant roles in prominent organizations, including Eisai US and The Ohio State University, and possesses strong leadership and communication skills.
Work at LifeMine Therapeutics
Jing Li currently serves as the Senior Director of Medicinal Chemistry at LifeMine Therapeutics, a position held since 2022. In this role, Li applies extensive expertise in medicinal chemistry to advance the company's drug development initiatives. The focus includes the design and synthesis of innovative drug candidates, particularly in the area of antibody-drug conjugates (ADCs). Li's leadership is instrumental in guiding research efforts and fostering collaboration within the organization.
Previous Experience at Eisai US
Prior to joining LifeMine Therapeutics, Jing Li worked at Eisai US in various capacities. From 2021 to 2022, Li held the position of Senior Principal Scientist in Cambridge, Massachusetts. Before that, from 2015 to 2021, Li served as Principal Scientist at the Eisai AiM Institute in Andover, Massachusetts. In these roles, Li contributed to drug development projects and collaborated with cross-functional teams to address drug safety and toxicity issues.
Educational Background and Expertise
Jing Li has a solid academic foundation in organic chemistry. Li earned a Doctor of Philosophy (Ph.D.) in Organic Chemistry from Lanzhou University, where studies spanned from 1994 to 1997. Prior to this, Li obtained a Master's degree in the same field from Lanzhou University from 1991 to 1994. Li's education is complemented by extensive research experience, including a postdoctoral position at The Ohio State University, which further developed expertise in synthetic chemistry and drug design.
Leadership and Management Skills
Jing Li possesses strong leadership and management skills, demonstrated through roles that require effective communication and collaboration across multiple units. Li has experience in managing research teams and external collaborations, ensuring alignment on project goals and fostering a productive work environment. This ability to lead diverse teams is critical in advancing complex drug development projects.
Research Contributions and Specializations
Jing Li has made significant contributions to the field of medicinal chemistry, particularly in linker chemistry and the design and synthesis of new antibody-drug conjugates (ADCs). Li's expertise extends to the development of PET tracers using isotopes such as 11C, 18F, and 3H. Additionally, Li has a strong background in intellectual property analysis, patent filing strategies, and application, which supports the innovation process in drug development.